Global Spatial Genomics and Transcriptomics Market

2.1    Primary Data Sources
2.2    Secondary Data Sources
2.3    Market Estimation Model
2.4    Criteria for Company Profiling

3.1    Spatial Biology: A Next-Generation Tissue Exploration Technology
3.2    Impact of COVID-19 on Spatial Omics Technology

4.1    Overview
4.2    Impact Analysis
4.3    Market Drivers
         4.3.1    Increasing Prevalence of Various Types of Genetic Disorders, Globally
         4.3.2    Technological Advancements in Sequencing Technologies
         4.3.3    Increasing Research Funding in the Field of Spatial Transcriptomics
4.4    Market Restraints
         4.4.1    High Capital Requirement Hampering the Expansion of Global Reach
         4.4.2    Lack of Tools for Computational Analysis
4.5    Market Opportunities
         4.5.1    Opportunity (by Product)
                      4.5.1.1    Services
         4.5.2    Opportunity (by Technology)
                     4.5.2.1    FISSEQ
4.6    Expansion into New Research Application such as Spatial Metagenomics
4.7    Expansion into Emerging Markets

5.1    Key Strategies and Development
         5.1.1    Product Launch and Upgradations
         5.1.2    Synergistic Activities
         5.1.3    Funding and Expansion
         5.1.4    Mergers and Acquisitions

6.1    Fresh Frozen Tissues
6.2    Fixed Frozen Tissues
6.3    Formalin Fixed Paraffin Embedded (FFPE) tissues
6.4    Cultured Cells

7.1    Kits and Assays
         7.1.1    Sample Preparation Kits
         7.1.2    Sample Enrichment Kits
7.2    Instrument
         7.2.1    Slide Scanner
         7.2.2    Microscopy
         7.2.3    Mass Cytometry
7.3    Software
7.4    Services

8.1    Spatial Imaging
         8.1.1    Laser Capture Microdissection (LCM)
         8.1.2    Immunohistochemistry (IHC)
         8.1.3    Fluorescent In-Situ Hybridization (FISH)
         8.1.4    Microscopy
         8.1.5    Barcodes
         8.1.6    Other
8.2    Spatial Sequencing
         8.2.1    Next-Generation Sequencing (NGS)
         8.2.2    In-Vivo Transcription
         8.2.3    Fluorescent In-Situ Sequencing (FISSEQ)
         8.2.4    Microtomy Sequencing
         8.2.5    Other
8.3    Spatial Analysis
         8.3.1    Data Visualization Tools
         8.3.2    Data Analysis Tools

9.1    Diagnostics
         9.1.1    Cancer Diagnostics
         9.1.2    Neurology Diagnostics
         9.1.3    Immunology Diagnostics
         9.1.4    Other Diagnostics
9.2    Translation Research
9.3    Drug Discovery and Development
9.4    Single Cell Analysis
9.5    Cell Biology
9.6    Other

10.1    Academic and Research Institutions
10.2    Biopharmaceutical and Biotechnological Companies
10.3    Contract Research Organization
10.4    Other End Users

11.1    Overview
11.2    North America
           11.2.1    U.S.
           11.2.2    Canada
11.3    Europe
           11.3.1    Germany
           11.3.2    France
           11.3.3    U.K.
           11.3.4    Italy
           11.3.5    Spain
           11.3.6    Rest-of-Europe
11.4    Asia-Pacific
           11.4.1    China
           11.4.2    Japan
           11.4.3    Australia
           11.4.4    India
           11.4.5    Singapore
           11.4.6    Rest-of-APAC
11.5    Latin America
           11.5.1    Brazil
           11.5.2    Mexico
           11.5.3    Rest-of-Latin America
11.6    Rest-of-the-World

12.1    Fluidigm Corporation
           12.1.1    Company Overview
           12.1.2    Role of Fluidigm Corporation in Global Spatial Genomics and Transcriptomics Market
           12.1.3    Financials
           12.1.4    Key Insights About Financial Health of the Company
           12.1.5    SWOT Analysis
12.2    10x Genomics, Inc.
           12.2.1    Company Overview
           12.2.2    Role of 10x Genomics, Inc. in Global Spatial Genomics and Transcriptomics Market
           12.2.3    Financials
           12.2.4    Key Insights About Financial Health of the Company
           12.2.5    SWOT Analysis
12.3    NanoString Technologies, Inc.
           12.3.1    Company Overview
           12.3.2    Role of NanoString Technologies, Inc. in Global Spatial Genomics and Transcriptomics Market
           12.3.3    Key Insights About Financial Health of the Company
           12.3.4    SWOT Analysis
12.4    Bio-Techne Corporation
           12.4.1    Company Overview
           12.4.2    Role of Bio-Techne Corporation in Global Spatial Genomics and Transcriptomics Market
           12.4.3    Key Insights About Financial Health of the Company
           12.4.4    SWOT Analysis
12.5    Flagship Biosciences, Inc.
           12.5.1    Company Overview
           12.5.2    Role of Flagship Biosciences, Inc. in Global Spatial Genomics and Transcriptomics Market
           12.5.3    SWOT Analysis
12.6    Akoya Biosciences, Inc.
           12.6.1    Company Overview
           12.6.2    Role of Akoya Biosciences, Inc. in Global Spatial Genomics and Transcriptomics Market
           12.6.3    SWOT Analysis
12.7    BioSpyder Technologies
           12.7.1    Company Overview
           12.7.2    Role of BioSpyder Technologies in Global Spatial Genomics and Transcriptomics Market
           12.7.3    SWOT Analysis
12.8    S2 Genomics, Inc.
           12.8.1    Company Overview
           12.8.2    Role of S2 Genomics, Inc. in Global Spatial Genomics and Transcriptomics Market
           12.8.3    SWOT Analysis
12.9    IONpath, Inc.
           12.9.1    Company Overview
           12.9.2    Role of IONpath, Inc. in Global Spatial Genomics and Transcriptomics Market
           12.9.3    SWOT Analysis
12.10    Miltenyi Biotec
             12.10.1    Company Overview
             12.10.2    Role of Miltenyi Biotec in Global Spatial Genomics and Transcriptomics Market
             12.10.3    SWOT Analysis
12.11    RareCyte, Inc.
             12.11.1    Company Overview
             12.11.2    Role of RareCyte, Inc. in Global Spatial Genomics and Transcriptomics Market
             12.11.3    SWOT Analysis
12.12    Visikol, Inc.
             12.12.1    Company Overview
             12.12.2    Role of Visikol, Inc. in Global Spatial Genomics and Transcriptomics Market
             12.12.3    SWOT Analysis

Table 4.1:    Likert Scale
Table 4.2:    Impact Analysis of Market Drivers
Table 4.3:    Impact Analysis of Market Restraints

Figure 1:    Global Neurological Disorder Burden, 2020
Figure 2:    Global Health Estimates 2030, Deaths by Age
Figure 3:    Impact Analysis of Market Drivers and Market Challenges on the Global Spatial Genomics and Transcriptomics Market
Figure 4:    Global Spatial Genomics and Transcriptomics Market (by Product Type),  $Million, 2020 vs. 2030
Figure 5:    Global Spatial Genomics and Transcriptomics Market (by Application), $Million , 2020 vs. 2030
Figure 6:    Global Spatial Genomics and Transcriptomics Market (by Sample Type), $Million , 2020 vs. 2030
Figure 7:    Global Spatial Genomics and Transcriptomics Market (by Workflow), $Million, 2020 vs. 2030
Figure 8:    Global Spatial Genomics and Transcriptomics Market (by End User),  $Million, 2020 vs. 2030
Figure 9:    Global Spatial Genomics and Transcriptomics Market Snapshot
Figure 1.1:    Global Spatial Genomics and Transcriptomics Market Segments
Figure 2.1:    Primary Research Methodology
Figure 2.2:    Bottom-Up Approach (Segment-Wise Analysis)
Figure 2.3:    Top-Down Approach (Segment-Wise Analysis)
Figure 4.1:    U.S. Prevalence of Lyme Disease 2009-2018:
Figure 4.2:    Global Prevalence Rate of Selected Rare Diseases Per 100,000 People
Figure 4.3:    Global Spatial Genomics and Transcriptomics Market (Service), 2020 and 2030
Figure 4.4:    Global Spatial Genomics and Transcriptomics Market (FISSEQ), 2020 and 2030
Figure 5.1:    Share of Key Developments and Strategies, 2017–2020
Figure 5.2:    Product Launch and Upgradation Share (by Company), 2017–2020
Figure 5.3:    Synergistic Activities Share (by Company), 2017–2020
Figure 5.4:    Funding and Expansion Share (by Company), 2017–2020
Figure 5.5:    Merger and Acquisition Share (by Company), 2017–2020
Figure 6.1:    Global Spatial Genomics and Transcriptomics Market (by Sample Type), $Million, 2019-2030
Figure 6.2:    Global Spatial Genomics and Transcriptomics Market (Fresh Frozen Tissues), $Million, 2019-2030
Figure 6.3:    Global Spatial Genomics and Transcriptomics Market (Fixed Frozen Tissues), $Million, 2019-2030
Figure 6.4:    Global Spatial Genomics and Transcriptomics Market (FFPE Tissues), $Million, 2019-2030
Figure 6.5:    Global Spatial Genomics and Transcriptomics Market (Cultured cells), $Million, 2019-2030
Figure 7.1:    Global Spatial Genomics and Transcriptomics Market (by Product Type), $Million, 2019-2030
Figure 7.2:    Global Spatial Genomics and Transcriptomics Market (Kits and Assays), $Million, 2019-2030
Figure 7.3:    Global Spatial Genomics and Transcriptomics Market (Sample Preparation Kits), $Million, 2019-2030
Figure 7.4:    Global Spatial Genomics and Transcriptomics Market (Sample Enrichment Kits), $Million, 2019-2030
Figure 7.5:    Global Spatial Genomics and Transcriptomics Market (Instrument), $Million, 2019-2030
Figure 7.6:    Global Spatial Genomics and Transcriptomics Market (Slide Scanner), $Million, 2019-2030
Figure 7.7:    Global Spatial Genomics and Transcriptomics Market (Microscopy), $Million, 2019-2030
Figure 7.8:    Global Spatial Genomics and Transcriptomics Market (Mass Cytometry), $Million, 2019-2030
Figure 7.9:    Global Spatial Genomics and Transcriptomics Market (Software), $Million, 2019-2030
Figure 7.10:    Global Spatial Genomics and Transcriptomics Market (Services), $Million, 2019-2030
Figure 8.1:    Global Spatial Genomics and Transcriptomics Market (by Workflow), $Million, 2019-2030
Figure 8.2:    Global Spatial Genomics and Transcriptomics Market (Spatial Imaging), $Million, 2019-2030
Figure 8.3:    Global Spatial Genomics and Transcriptomics Market (Laser Capture Microdissection), $Million, 2019-2030
Figure 8.4:    Global Spatial Genomics and Transcriptomics Market (IHC), $Million, 2019-2030
Figure 8.5:    Global Spatial Genomics and Transcriptomics Market ( FISH), $Million, 2019-2030
Figure 8.6:    Global Spatial Genomics and Transcriptomics Market (Microscopy), $Million, 2019-2030
Figure 8.7:    Global Spatial Genomics and Transcriptomics Market (Barcodes), $Million, 2019-2030
Figure 8.8:    Global Spatial Genomics and Transcriptomics Market (Other), $Million,  2019-2030
Figure 8.9:    Global Spatial Genomics and Transcriptomics Market (by Spatial Sequencing), $Million, 2019-2030
Figure 8.10:    Global Spatial Genomics and Transcriptomics Market (NGS), $Million, 2019-2030
Figure 8.11:    Global Spatial Genomics and Transcriptomics Market (In-Vivo Transcription), $Million, 2019-2030
Figure 8.12:    Global Spatial Genomics and Transcriptomics Market (FISSEQ), $Million, 2019-2030
Figure 8.13:    Global Spatial Genomics and Transcriptomics Market (Microtomy Sequencing), $Million, 2019-2030
Figure 8.14:    Global Spatial Genomics and Transcriptomics Market (Other Sequencing), $Million, 2019-2030
Figure 8.15:    Global Spatial Genomics and Transcriptomics Market (by Spatial Analysis), $Million, 2019-2030
Figure 8.16:    Global Spatial Genomics and Transcriptomics Market (Data Visualization Tool), $Million, 2019-2030
Figure 8.17:    Global Spatial Genomics and Transcriptomics Market (Data Analysis Tools), $Million, 2019-2030
Figure 9.1:    Global Spatial Genomics and Transcriptomics Market (by Application), $Million, 2019-2030
Figure 9.2:    Global Spatial Genomics and Transcriptomics Market (by Diagnostics), $Million, 2019-2030
Figure 9.3:    Global Spatial Genomics and Transcriptomics Market (Cancer Diagnostics), $Million, 2019-2030
Figure 9.4:    Global Spatial Genomics and Transcriptomics Market (Neurology Diagnostics), $Million, 2019-2030
Figure 9.5:    Global Spatial Genomics and Transcriptomics Market (Immunology Diagnostics), $Million, 2019-2030
Figure 9.6:    Global Spatial Genomics and Transcriptomics Market (Other Diagnostics), $Million, 2019-2030
Figure 9.7:    Global Spatial Genomics and Transcriptomics Market (Translational Research), $Million, 2019-2030
Figure 9.8:    Global Spatial Genomics and Transcriptomics Market (Drug Discovery and Development), $Million, 2019-2030
Figure 9.9:    Global Spatial Genomics and Transcriptomics Market (Single Cell Analysis), $Million, 2019-2030
Figure 9.10:    Global Spatial Genomics and Transcriptomics Market (Cell Biology), $Million, 2019-2030
Figure 9.11:     Global Spatial Genomics and Transcriptomics Market (by Others), $Million, 2019-2030
Figure 10.1:    Global Spatial Genomics and Transcriptomics Market (by End User), $Million, 2019-2030 $Million
Figure 10.2:    Global Spatial Genomics and Transcriptomics Market (Academic and Research Institutions), $Million, 2019-2030
Figure 10.3:    Global Spatial Genomics and Transcriptomics Market (Biopharmaceutical and Biotech Companies), $Million, 2019-2030
Figure 10.4:    Global Spatial Genomics and Transcriptomics Market (Contract Research Organization), $Million, 2019-2030
Figure 10.5:    Global Spatial Genomics and Transcriptomics Market (Other End User), $Million, 2019-2030
Figure 11.1:    Global Spatial Genomics and Transcriptomics Market (by Region), $Million, 2020 and 2030
Figure 11.2:    Global Spatial Genomics and Transcriptomics Market (by Region), $Million, 2019-2030
Figure 11.3:    North America Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.4:    North America: Market Dynamics
Figure 11.5:    North America Spatial Genomics and Transcriptomics Market (by Country), 2019-2030
Figure 11.6:    U.S. Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.7:    Canada Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.8:    Europe Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.9:    Europe: Market Dynamics
Figure 11.10:    Europe Spatial Genomics and Transcriptomics Market (by Country), $Million, 2019-2030
Figure 11.11:    Germany Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.12:    France Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.13:    U.K. Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.14:    Italy Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.15:    Spain Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.16:    Rest-of-Europe Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.17:    Asia-Pacific Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.18:    APAC: Market Dynamics
Figure 11.19:    APAC Spatial Genomics and Transcriptomics Market (by Country), $Million, 2019-2030
Figure 11.20:    China Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.21:    Japan Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.22:    Australia Spatial Genomics and Transcriptomics Sequencing Market, $Million, 2019-2030
Figure 11.23:    India Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.24:    Singapore Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.25:    RoAPAC Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.26:    Latin America Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.27:    Latin America: Market Dynamics
Figure 11.28:    Latin America Spatial Genomics and Transcriptomics Market (by Country), 2019-2030
Figure 11.29:    Brazil Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.30:    Mexico Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.31:    Rest-of-Latin America Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 11.32:    RoW Spatial Genomics and Transcriptomics Market, $Million, 2019-2030
Figure 12.1:    Total Number of Companies Profiled
Figure 12.2:    Fluidigm Corporation: Product Portfolio
Figure 12.3:    Fluidigm Corporation: Overall Financials, 2017-2019
Figure 12.4:    Fluidigm Corporation: Revenue (by Business Segment), 2017-2019
Figure 12.5:    Fluidigm Corporation.: Revenue (by Region), 2017-2019
Figure 12.6:    Fluidigm Corporation: R&D Expenditure, 2017-2019
Figure 12.7:    Fluidigm Corporation: SWOT Analysis
Figure 12.8:    10x Genomics, Inc.: Product Portfolio
Figure 12.9:    10x Genomics, Inc.: Overall Financials, 2017-2019
Figure 12.10:    10x Genomics, Inc.: Revenue (by Business Segment), 2017-2019
Figure 12.11:    10x Genomics, Inc.: Revenue (by Region), 2017-2019
Figure 12.12:    10x Genomics, Inc.: R&D Expenditure, 2017-2019
Figure 12.13:    10x Genomics, Inc.: SWOT Analysis
Figure 12.14:    NanoString Technologies, Inc.: Product Portfolio
Figure 12.15:    NanoString Technologies, Inc.: Overall Financials, (2017-2019)
Figure 12.16:    NanoString Technologies, Inc.: Revenue (by Business Segment), 2017-2019
Figure 12.17:    NanoString Technologies, Inc.: Revenue (by Region), 2017-2019
Figure 12.18:    NanoString Technologies, Inc.: R&D Expenditure, 2017-2019
Figure 12.19:    NanoString Technologies, Inc.: SWOT Analysis
Figure 12.20:    Bio-Techne Corporation: Product Portfolio
Figure 12.21:    Bio-Techne Corporation: Overall Financials, 2018-2020
Figure 12.22:    Bio-Techne Corporation: Revenue (by Business Segment), 2018-2020
Figure 12.23:    Bio-Techne Corporation: Revenue (by Region), 2018-2020
Figure 12.24:    Bio-Techne Corporation: R&D Expenditure, 2018-2020
Figure 12.25:    Bio-Techne Corporation: SWOT Analysis
Figure 12.26:    Flagship Biosciences, Inc.: Overall Product Portfolio
Figure 12.27:    Flagship Biosciences, Inc.: SWOT Analysis
Figure 12.28:    Akoya Biosciences, Inc.: Overall Product Portfolio
Figure 12.29:    Akoya Biosciences, Inc.: SWOT Analysis
Figure 12.30:    BioSpyder Technologies: Overall Product Portfolio
Figure 12.31:    BioSpyder Technologies: SWOT Analysis
Figure 12.32:    S2 Genomics, Inc.: Overall Product Portfolio
Figure 12.33:    S2 Genomics, Inc.: SWOT Analysis
Figure 12.34:    IONpath, Inc.: Overall Product Portfolio
Figure 12.35:    IONpath, Inc.: SWOT Analysis
Figure 12.36:    Miltenyi Biotec: Overall Product Portfolio
Figure 12.37:    Miltenyi Biotec: SWOT Analysis
Figure 12.38:    RareCyte, Inc.: Overall Product Portfolio
Figure 12.39:    RareCyte, Inc.: SWOT Analysis
Figure 12.40:    Visikol, Inc.: Overall Product Portfolio
Figure 12.41:    Visikol, Inc.: SWOT Analysis